Cypress Capital Group Has $1.71 Million Stake in Stryker Corporation $SYK

Cypress Capital Group trimmed its holdings in Stryker Corporation (NYSE:SYK) by 4.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,312 shares of the medical technology company’s stock after selling 183 shares during the period. Cypress Capital Group’s holdings in Stryker were worth $1,706,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. CCG Wealth Management LLC acquired a new position in Stryker during the second quarter valued at approximately $216,000. Mitchell Sinkler & Starr PA raised its position in Stryker by 2.0% during the second quarter. Mitchell Sinkler & Starr PA now owns 6,425 shares of the medical technology company’s stock valued at $2,542,000 after purchasing an additional 124 shares in the last quarter. CWM LLC raised its position in Stryker by 1.6% during the second quarter. CWM LLC now owns 17,652 shares of the medical technology company’s stock valued at $6,984,000 after purchasing an additional 282 shares in the last quarter. OFI Invest Asset Management raised its position in Stryker by 37.4% during the second quarter. OFI Invest Asset Management now owns 3,623 shares of the medical technology company’s stock valued at $1,433,000 after purchasing an additional 986 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Stryker by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 52,869 shares of the medical technology company’s stock valued at $20,918,000 after purchasing an additional 9,436 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on SYK. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Finally, Needham & Company LLC boosted their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $430.10.

Stryker Stock Performance

Shares of Stryker stock opened at $364.77 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The stock has a market cap of $139.45 billion, a price-to-earnings ratio of 48.31, a P/E/G ratio of 2.63 and a beta of 0.94. The company’s fifty day moving average is $380.25 and its 200 day moving average is $378.90.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the previous year, the firm posted $2.81 earnings per share. Stryker’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.